What are health insurance stocks?

Health insurers can be divided into segments including individual plans, family plans, and employer-sponsored group coverage. In the US market, Medicare and Medicaid provide insurance services to elderly and low-income Americans respectively, and some healthcare insurers produce the majority of their revenue from specialised products targeting these sectors.

The health insurance sector is under pressure from demographic shifts, evolving care delivery models, and changing government priorities. The most significant long-term trend affecting health insurers is demographic transition, as the (disproportionately large, in the USA) baby boomer generation ages. This age group, born in the 1940s and 1950s, are now mostly eligible for age-related benefits such as Medicare, while the median age of the US has increased from just under 29 in 1970 to 39 in 2025. The large size of this older generation has increased overall healthcare investment costs and leads to greater per-person expenses for insurers, with Medicare and Medicaid insurance providers targeting this market with dedicated products. Other trends, which also increase expectations and cost pressure for health insurers, include personalised healthcare and price transparency.

Rising prescription drug costs are a major challenge for health insurers, with specialty medications and expensive new therapies (such as biotech treatments) creating unprecedented cost pressures. Healthcare insurance companies manage these costs by through tied deals with pharmacies, which increase the end cost of drugs to policy holders but guarantee stable profits on common medications, split between the pharmacy and insurer. The increasing prevalence of high-cost specialty drugs for chronic conditions adds extra costs for insurers, leading to more selective authorisation and increasing policy costs.

Health insurance companies, like those in the pharmaceuticals or elsewhere in the financial sector, operate under strict regulation. Federal and state policy changes can significantly impact market participation and profitability, and other trends, such as increasing drug costs and tighter policy restrictions, increase the likelihood of eventual regulatory intervention. Ongoing debates around Medicare for All proposals, Medicaid expansion, and individual market stabilisation have created regulatory uncertainty that influences strategic planning and capital allocation decisions. For investors, these factors can contribute to unpredictable spikes in volatility in what is generally considered a defensive, income-generating stock sector.